Amicus Therapeutics Inc (FOLD)

7.480
-0.010(-0.13%)
After Hours
7.810
+0.330(+4.412%)
- Real-time Data
  • Volume:
    2,567,666
  • Day's Range:
    7.405 - 7.730
  • 52 wk Range:
    5.910 - 12.630

FOLD Overview

Prev. Close
7.49
Day's Range
7.405-7.73
Revenue
317.83M
Open
7.49
52 wk Range
5.91-12.63
EPS
-0.97
Volume
2,567,666
Market Cap
2.1B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,706,398
P/E Ratio
-
Beta
1.39
1-Year Change
-21.07%
Shares Outstanding
280,162,619
Next Earnings Date
Aug 10, 2022
What is your sentiment on Amicus?
or
Market is currently closed. Voting is open during market hours.

Amicus Therapeutics Inc News

Amicus Therapeutics Inc Analysis

Amicus Therapeutics Inc Company Profile

Amicus Therapeutics Inc Company Profile

Employees
496

Amicus Therapeutics, Inc. is a biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellNeutralNeutralStrong Sell
Technical IndicatorsStrong SellStrong SellStrong BuyBuyStrong Sell
SummaryStrong SellStrong SellBuyNeutralStrong Sell
  • I wish i could be the CEO of the company. He sold his stocks accidentally on friday.
    0
    • I also sold at 8.8 after almost 2 years of bagholding. Now it's up
      0
  • 04.11 = MA 50 crossed above the MA200
    0
    • monthly return= -25%
      0
      • Been spendin' most their livesLivin' in a shorters's paradise(4x)
        0
    • For 2021, the company expects total Galafold revenues of at least $300-$315 million, driven by continued operational growth and commercial execution across all major markets, including the United States, the EU, the U.K. and Japan.
      0
      • buying, crashing in 2 days, bagholding for a year to breakeven, crashing in 2 days, repeat
        0
    • with WH already worked, waiting here
      0
      • just sent to WSB the offer to try short squuze with WH and FOLD, let's see
        0
        • hahaah tnx
          0
      • why is it going down today?
        0
        • Avoid any recommendations (it's monkey business for big) use your brain and intuition, then you save your own money.
          0
          • O co chodzi, Wojciech?
            0
          • Miguel Angel Cuña I've been investing for more then four years from now. So, I followed, at the begining, recommendations given by so called experts. More then 60% of its were wrong or disapointed me. Now I know that my estimation of stock and intuition is no worse and some times better then experts from banks, etc. I try to follow Buffet's point of view in investing, of course, reading all opinions and recommendations given.
            0
        • I was right: *****and see you next year!
          2
          • Going south, 7, 5 or very bottom $2? Amicus=amicable or .... reverse.
            3